Skip navigation

Pharma's Market

PHARMA WATCH LIST
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

Current DateTime: 12:55:29 10 Feb 2012
LinksList Documentid: 23279705
Expiration DateTime: 2/10/2012 12:56:05 PM

SPECIAL REPORT


Current DateTime: 12:55:30 10 Feb 2012
LinksList Documentid: 32984624

MOST SHARED


Current DateTime: 12:55:30 10 Feb 2012
LinksList Documentid: 31330905
Expiration DateTime: 2/10/2012 12:57:45 PM

Current DateTime: 12:55:30 10 Feb 2012
LinksList Documentid: 23452000
Expiration DateTime: 2/10/2012 12:57:40 PM

Current DateTime: 12:55:30 10 Feb 2012
LinksList Documentid: 23452764
Expiration DateTime: 2/10/2012 12:57:24 PM

PHARMA'S MARKET VIDEO

» More

Current DateTime: 12:55:33 10 Feb 2012
LinksList Documentid: 31171988
Expiration DateTime: 2/10/2012 12:57:08 PM

RSS FEED

» Help

Current DateTime: 12:55:33 10 Feb 2012
LinksList Documentid: 31171995

Prana Biotechnology: Why I Wanted To Do Their Story

Published: Tuesday, 26 Feb 2008 | 1:13 PM ET
Text Size
By: Mike Huckman
Reporter

I often get pitched by PR people who want me to do a story on their micro-cap biotech company. And I almost always turn them down. I know that most of the sector toils in the eight and nine digit market value space and that there's a bit of a Catch-22 at work. I mean, how can a micro-cap get any bigger if they aren't given more attention and a higher profile when they've got news? I get it.

But there's not much I can do about it. There's a limited amount of airtime on CNBC and whether it's biotech or any other sector, management draws the line on the market cap of companies that we'll highlight. But there are exceptions to the rule. And today there's an example.

Prana Biotechnology [PRAN  Loading...      ()   ] started out the trading day in the U.S. with a market value of about $75 million. On relatively heavy volume--as I write this--it's crossed the $100 million threshold. Typically not a company I'd be permitted to spend any time covering. But here's why I was able to "sell" what in TV-news lingo we call a "hit" (approximately one minute or the equivalent of maybe two inches of copy in a newspaper) to the producers of "Squawk on the Street" this morning: (You can watch it in the video clip.)

A. It's Alzheimer's Disease, a burgeoning epidemic that affects a lot of viewers.

B. The mostly positive results are from a mid-stage test. That increases the likelihood in today's environment that a pipeline-poor, cash-rich big drug company might come along and partner with or take out the company which doesn't have the money to pay for a large, late-stage clinical trial.

To PR folks who might be reading this, please don't interpret the coverage as setting any kind of precedent and start flooding my inbox or voicemail with a bunch of micro-cap pitches. This was a one-and-done report. In other words, I'm not doing the story on any other CNBC shows today with the exception, of course, of writing about it on this blog. And editorial decisions are made on a case by case basis.

Prana is sanskrit for life force. Namaste.

Questions?  Comments? 
© 2012 CNBC, Inc. All Rights Reserved


Current DateTime: 09:37:12 10 Feb 2012
LinksList Documentid: 29778428

Current DateTime: 09:37:11 10 Feb 2012
LinksList Documentid: 29779196

Current DateTime: 11:35:13 10 Feb 2012
LinksList Documentid: 29779197

Current DateTime: 09:37:12 10 Feb 2012
LinksList Documentid: 29779199
CNBCCNBC
About CNBC  |  Site Map  |  Video Reprints   |  Advertise  |  Help  |  Contact
Privacy Policy  |     |  Terms of Service  |  Independent Programming Report
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2012 CNBC LLC.  All Rights Reserved.
A Division of NBCUniversal
Thomson ReutersThomson Reuters